IIOT-OXYS (ITOX) 10-Q 15 Nov 21 2021 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2021	Nov. 11, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2021
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity File Number	000-50773
Entity Registrant Name	IIOT-OXYS Inc.
Entity Central Index Key	0001290658
Entity Tax Identification Number	56-2415252
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	705 Cambridge Street
Entity Address, City or Town	Cambridge
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02141
City Area Code	(401)
Local Phone Number	307-3092
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		215,854,396

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Current Assets
Cash and cash equivalents	$ 103,013	$ 103,074
Accounts receivable, net	5,280	0
Prepaid expenses	7,773	2,427
Total Current Assets	116,066	105,501
Intangible assets, net	310,562	347,856
Total Assets	426,628	453,357
Current Liabilities
Accounts payable	180,081	169,914
Accrued liabilities	211,860	147,490
Deferred revenue	46,425	46,425
Notes payable, current portion, net of debt discounts of $202,048 and $111,781 at September 30, 2021 and December 31, 2020, respectively	431,119	953,219
Shares payable to related parties	361,800	730,836
Salaries payable to related parties	270,854	407,271
Derivative liability	143,224	315,782
Total Current Liabilities	1,645,363	2,770,937
PPP liability	36,700	36,700
Due to stockholders	1,000	1,000
Total Liabilities	1,683,063	2,808,637
Commitments and contingencies (Note 4)
Series B Convertible Preferred Stock, 600 shares designated, $0.001 par value, $1,200 stated value; 155 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively. Liquidation preference $186,000 as of September 30, 2021 and December 31, 2020, respectively	186,000	186,000
Stockholders' Equity (Deficit)
Preferred Stock Series A, $0.001 par value, 10,000,000 Shares authorized; 25,845 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively	26	26
Common Stock $0.001 par value, 1,000,000,000 shares authorized; 215,854,396 shares and 145,110,130 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively	215,855	145,111
Additional paid in capital	6,640,573	4,794,261
Accumulated deficit	(8,298,889)	(7,480,678)
Total stockholders' equity (deficit)	(1,442,435)	(2,541,280)
Total Liabilities and Stockholders' Equity (Deficit)	$ 426,628	$ 453,357

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Debt discount	$ 202,048	$ 111,781
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, par value	$ 0.001	$ 0.001
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, shares issued	215,854,396	145,110,130
Common stock, shares outstanding	215,854,396	145,110,130
Series B Convertible Preferred Stock [Member]
Preferred stock, shares authorized	600	600
Preferred stock, par value	$ 1,200	$ 1,200
Preferred stock, shares issued	155	155
Preferred stock, shares outstanding	155	155
Liquidation preference	$ 186,000	$ 186,000
Series A Preferred Stock [Member]
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares issued	25,845	25,845
Preferred stock, shares outstanding	25,845	25,845

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Statement [Abstract]
Revenues	$ 5,280	$ 0	$ 5,280	$ 41,771
Cost of sales	1,275	0	1,275	21,121
Gross Profit	4,005	0	4,005	20,650
Operating Expenses
General and administrative	7,569	11,121	22,009	40,056
Payroll expense	112,541	0	250,820	0
Professional fees	88,421	240,919	464,917	672,256
Patent license fees	0	1,644	0	4,932
Amortization of intangible assets	12,477	12,477	37,295	37,159
Total Operating Expenses	221,008	266,161	775,041	754,403
Other Income (Expense)
Gain (loss) on change in FMV of derivative liability	(18,103)	25,181	172,558	(114,051)
Gain (loss) on extinguishment of debt	0	(16,205)	120,000	(16,205)
Interest expense	(100,701)	(72,681)	(333,039)	(640,404)
Other Income	10,000	0	10,000	409
Total Other Income (Expense)	(108,804)	(63,705)	(30,481)	(770,251)
Net Loss Before Income Taxes	(325,807)	(329,866)	(801,517)	(1,504,004)
Provision for income tax	0	0	0	0
Net Loss	(325,807)	(329,866)	(801,517)	(1,504,004)
Convertible preferred stock dividend	(5,626)	0	(16,694)	0
Net Loss Attributable to Common Stockholders	$ (331,433)	$ (329,866)	$ (818,211)	$ (1,504,004)
Net Loss Per Share Attributable to Common Stockholders - Basic and Diluted	$ 0	$ 0	$ 0	$ (0.02)
Weighted Average Shares Outstanding Attributable to Common Stockholders - Basic and Diluted	209,650,048	98,736,959	188,036,903	99,156,375

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2019		$ 43,314	$ 3,077,972	$ (5,040,307)	$ (1,919,021)
Beginning balance, shares at Dec. 31, 2019		43,313,547
Common stock issued for debt extinguishment		$ 6,760	9,992		16,752
Common stock issued for extinguishment of debt, shares		6,760,000
Common stock issued for conversion of convertible note payables		$ 50,950	1,686		52,636
Common stock issued for conversion of convertible note payables, shares		50,950,000
Common stock issued for conversion of detachable warrants		$ 40,802	(40,802)
Common stock issued for conversion of detachable warrants, Shares		40,802,082
Relief of derivative liabilities			235,393		235,393
Warrants issued for default of convertible note payables			163,433		163,433
Changes in FMV of warrants related to convertible note payables			203,597	(203,597)
Beneficial conversion feature discount on note payable			26,833		26,833
Net loss				(1,504,004)	(1,504,004)
Ending balance, value at Sep. 30, 2020		$ 141,826	3,678,104	(6,747,908)	(2,927,978)
Ending balance, shares at Sep. 30, 2020		141,825,629
Beginning balance, value at Jun. 30, 2020		$ 135,066	3,668,112	(6,418,042)	(2,614,864)
Beginning balance, shares at Jun. 30, 2020		135,065,629
Common stock issued for debt extinguishment		$ 6,760	9,992		16,752
Common stock issued for extinguishment of debt, shares		6,760,000
Net loss				(329,866)	(329,866)
Ending balance, value at Sep. 30, 2020		$ 141,826	3,678,104	(6,747,908)	(2,927,978)
Ending balance, shares at Sep. 30, 2020		141,825,629
Beginning balance, value at Dec. 31, 2020	$ 26	$ 145,111	4,794,261	(7,480,678)	(2,541,280)
Beginning balance, shares at Dec. 31, 2020	25,845	145,110,129
Common stock issued for conversion of convertible note payables		$ 32,351	291,169		323,520
Common stock issued for conversion of convertible note payables, shares		32,350,978
Common stock sold for cash		$ 35,500	497,000		532,500
Common stock sold for cash, shares		35,500,000
Beneficial conversion feature discount on note payable			360,000		360,000
Commission paid for raising capital			(10,650)		(10,650)
Common stock issued for accrued compensation		$ 2,343	700,643		702,986
Common stock issued for accrued compensation, Shares		2,343,288
Common stock issued for services		$ 550	8,150		8,700
Common stock issued for services, Shares		550,000
Net loss				(818,211)	(818,211)
Ending balance, value at Sep. 30, 2021	$ 26	$ 215,855	6,640,573	(8,298,889)	(1,442,435)
Ending balance, shares at Sep. 30, 2021	25,845	215,854,395
Beginning balance, value at Jun. 30, 2021	$ 26	$ 197,655	6,428,833	(7,967,456)	(1,340,942)
Beginning balance, shares at Jun. 30, 2021	25,845	197,654,395
Common stock issued for conversion of convertible note payables		$ 8,000	72,000		80,000
Common stock issued for conversion of convertible note payables, shares		8,000,000
Common stock sold for cash		$ 10,200	142,800		153,000
Common stock sold for cash, shares		10,200,000
Commission paid for raising capital			(3,060)		(3,060)
Net loss				(331,433)	(331,433)
Ending balance, value at Sep. 30, 2021	$ 26	$ 215,855	$ 6,640,573	$ (8,298,889)	$ (1,442,435)
Ending balance, shares at Sep. 30, 2021	25,845	215,854,395

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash Flows From Operating Activities
Net loss	$ (818,211)	$ (1,504,004)
Adjustments to reconcile net loss to net cash used in operating activities
Gain on extinguishment of debt	(120,000)	16,205
Loss on issuance of default warrants	0	163,433
Increase in principal due to penalty provision	0	146,250
Increase in principal due to fees	0	16,726
Beneficial conversion feature discount on notes payable	0	0
Amortization of discount on notes payable	269,734	90,149
Amortization of intangible assets	37,295	37,159
Loss on change in FMV of derivative liability	0	114,051
Loss on derivative liability	0	159,888
Increase (Decrease) in:
Accounts receivable	(5,280)	11,760
Prepaid expense	(5,346)	1,282
Accounts payable	10,167	37,371
Accrued liabilities	84,757	24,267
Derivative liability	(172,558)
Deferred revenue	0	46,425
Shares payable to related parties	333,950	545,673
Salaries payable to related parties	(136,417)	51,648
Net Cash Used in Operating Activities	(521,911)	(41,717)
Cash Flows From Financing Activities
Cash received from PPP loan	0	36,700
Cash received from Convertible Note Payable	0	129,300
Proceeds from sale of common stock, net of commissions	521,850	0
Cash paid for settlement of notes payable	0	(100,000)
Net Cash Provided By Financing Activities	521,850	66,000
Net (decrease) increase in cash and cash equivalents	(61)	24,283
Cash and Cash Equivalents - Beginning of Period	103,074	24,212
Cash and Cash Equivalents - End of Period	103,013	48,495
Supplement Disclosures of Cash Flow Information
Interest paid during the period	0	0
Income taxes paid during the period	0	31,902
Supplemental Disclosures of Non-Cash Investing and Financing Activities
Discount on notes payable	360,000	0
Conversion of convertible notes payable and derivative liabilities	1,035,206	288,029
Warrant anti-dilution issuance	$ 0	$ 203,597

NATURE OF OPERATIONS, BASIS OF

NATURE OF OPERATIONS, BASIS OF PRESENTATION AND GOING CONCERN	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
NATURE OF OPERATIONS, BASIS OF PRESENTATION AND GOING CONCERN	NOTE 1 - NATURE OF OPERATIONS, BASIS OF PRESENTATION AND GOING CONCERN Unless otherwise indicated, any reference to “the Company”, “our company”, “we”, “us”, or “our” refers to IIOT-OXYS, Inc., a Nevada corporation, and as applicable to its wholly-owned subsidiaries, OXYS Corporation, a Nevada corporation, and HereLab, Inc., a Delaware corporation. IIOT-OXYS, Inc., a Nevada corporation (the “ Company We were incorporated in the state of New Jersey on October 1, 2003 under the name of Creative Beauty Supply Corporation and commenced operations as of January 1, 2004. On November 30, 2007, our Board of Directors approved a plan to dispose of our wholesale and retail beauty supply business. On May 18, 2015, we changed our name to Gotham Capital Holdings. From January 1, 2009 until July 28, 2017, we had no operations. On March 16, 2017, our Board of Directors approved a name change to “IIOT-OXYS, Inc.” and authorized a change of domicile from New Jersey to Nevada. Impact of COVID-19 During the period ended September 30, 2021, the effects of a new coronavirus (“ COVID-19 On March 11, 2020, the World Health Organization designated COVID-19 as a global pandemic. Governments around the world have mandated, and continue to introduce, orders to slow the transmission of the virus, including but not limited to shelter-in-place orders, quarantines, significant restrictions on travel, as well as work restrictions that prohibit many employees from going to work. Uncertainty with respect to the economic effects of the pandemic has introduced significant volatility in the financial markets. Basis of Presentation The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“ GAAP Going Concern The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As shown in the accompanying financial statements, the Company has suffered continuing operating losses, used cash flows in operating activities of $ 521,911 8,298,889 Management believes that the Company will be able to achieve a satisfactory level of liquidity to meet the Company’s obligations for the next 12 months by generating cash through additional borrowings and/or sale of equity securities, as needed. However, there can be no assurance that the Company will be able to generate sufficient liquidity to maintain its operations. The financial statements do not include any adjustments that might result from the outcome of these uncertainties.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The following summary of significant accounting policies of the Company is presented to assist in the understanding of the Company’s financial statements. These accounting policies conform to GAAP in all material respects and have been consistently applied in preparing the accompanying condensed consolidated financial statements. Interim Financial Statements The accompanying unaudited condensed interim financial statements and related notes have been prepared in accordance with GAAP for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission with respect to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited financial statements of the Company for the year ended December 31, 2020. Principles of Consolidation The condensed consolidated financial statements for September 30, 2021 and 2020, respectively, include the accounts of Company, and its wholly-owned subsidiaries OXYS Corporation and HereLab, Inc. All significant intercompany balances and transactions have been eliminated. Reclassifications Certain amounts in the prior periods presented have been reclassified to conform to the current period financial statement presentation. These reclassifications have no effect on previously reported net income. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the valuation of accounts payable, accrued liabilities and payable to related party. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. Cash and Cash Equivalents The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents. The Company reported a cash balance of $ 103,013 103,074 Accounts Receivable and Allowance for Doubtful Accounts Trade accounts receivable are carried at original invoice amount less an estimate made for doubtful accounts. The Company determines the allowance for doubtful accounts by identifying potential troubled accounts and by using historical experience and future expectations applied to an aging of accounts. Trade accounts receivable are written off when deemed uncollectible. Recoveries of trade accounts receivable previously written off are recorded as income when received. The Company recorded accounts receivable of $ 5,280 0 no Long-Lived Assets The Company regularly reviews the carrying value and estimated lives of its long-lived assets to determine whether indicators of impairment may exist that warrant adjustments to the carrying value or estimated useful lives. The determinants used for this evaluation include management’s estimate of the asset’s ability to generate positive income from operations and positive cash flow in future periods as well as the strategic significance of the assets to the Company’s business objectives. Definite-lived intangible assets are amortized on a straight-line basis over the estimated periods benefited and are reviewed when appropriate for possible impairment. Basic and Diluted Earnings (Loss) Per Common Share The Company computes earnings (loss) per share in accordance with Financial Accounting Standards Board Accounting Standards Codification (“ ASC Earnings per Share” EPS Revenue Recognition The Company’s revenue is derived primarily from providing services under contractual agreements. The Company recognizes revenue in accordance with ASC Topic No. 606, Revenue from Contracts with Customers According to ASC 606, the Company recognizes revenue based on the following criteria: · Identification of a contract or contracts, with a customer. · Identification of the performance obligations in the contract. · Determination of contract price. · Allocation of transaction price to the performance obligation. · Recognition of revenue when, or as, performance obligation is satisfied. The Company used a practical expedient available under ASC 606-10-65-1(f)4 that permits it to consider the aggregate effect of all contract modifications that occurred before the beginning of the earliest period presented when identifying satisfied and unsatisfied performance obligations, transaction price, and allocating the transaction price to the satisfied and unsatisfied performance obligations. The Company has elected to treat shipping and handling activities as cost of sales. Additionally, the Company has elected to record revenue net of sales and other similar taxes. Concentration of Credit Risk Financial instruments that potentially expose the Company to concentrations of risk consist primarily of cash and cash equivalents which are generally not collateralized. The Company’s policy is to place its cash and cash equivalents with high quality financial institutions, in order to limit the amount of credit exposure. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“ FDIC 250,000 no Fair Value of Financial Instruments and Fair Value Measurements ASC 820, “ Fair Value Measurements and Disclosures”, Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data. If the asset or liability has a specified (contractual) term, the Level 2 input must be observable for substantially the full term of the asset or liability. Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. The Company’s condensed consolidated financial instruments consist of cash and cash equivalents, prepaid expenses, accounts payable, accrued liabilities, notes payable and related parties payable. The Company believes that the recorded values of all the financial instruments approximate their current fair values because of their nature and respective maturity dates or durations. Income Taxes The Company accounts for income taxes using the asset and liability method in accordance with ASC 740, “ Income Taxes” The Company follows the provisions of ASC 740-10, “ Accounting for Uncertain Income Tax Positions Convertible Debt and Convertible Preferred Stock When the Company issues convertible debt or convertible preferred stock, it first evaluates the balance sheet classification of the convertible instrument in its entirety to determine whether the instrument should be classified as a liability under ASC 480, Distinguishing Liabilities from Equity Derivatives and Hedging If a conversion feature does not meet the conditions to be separated and accounted for as an embedded derivative liability, the Company then determines whether the conversion feature is “beneficial”. A conversion feature would be considered beneficial if the conversion feature is “in the money” when the host instrument is issued or, under certain circumstances, later. If convertible debt contains a beneficial conversion feature (“ BCF When a convertible preferred stock contains a BCF, after allocating the proceeds to the BCF, the resulting discount is either amortized over the period beginning when the convertible preferred stock is issued up to the earliest date the conversion feature may be exercised, or if the convertible preferred stock is immediately exercisable, the discount is fully amortized at the date of issuance. The amortization is recorded similar to a dividend. Convertible debt is accounted for under the ASC 470-20, Debt – Debt with Conversion and Other Options. Recent Accounting Pronouncements In December 2019, the Financial Accounting Standards Board issued Accounting Standards Update (“ ASU Income Taxes (Topic 740) In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU also removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and simplifies the diluted earnings per share calculation in certain areas. The amendments in this ASU are effective for annual and interim periods beginning after December 15, 2023, although early adoption is permitted. The Company is in the process of evaluating the impact of this new guidance on its financial statements. Other accounting standards that have been issued or proposed by FASB and do not require adoption until a future date are not expected to have a material impact on the consolidated financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.

INTANGIBLE ASSETS

INTANGIBLE ASSETS	9 Months Ended
	Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS	NOTE 3 - INTANGIBLE ASSETS The Company’s intangible assets comprise of intellectual property revolving around their field tests, sensor integrations, and board designs. Intangible assets, net of amortization at September 30, 2021 and December 31, 2020 amounted to $ 310,562 347,856 Intangible Assets Net of Amortization September 30, 2021 December 31, 2020 Intangible Assets $ 495,000 $ 495,000 Accumulated amortization (184,438 ) (147,144 ) Intangible Assets, net $ 310,562 $ 347,856 At September 30, 2021 and December 31, 2020, respectively, the Company determined that none 10 12,477 12,477 37,295 37,159 The following table summarizes the Company’s estimated future amortization expense of intangible assets with finite lives as of December 31: Schedule of future amortization Amortization expense 2021 $ 12,477 2022 49,500 2023 49,500 2024 49,500 2025 49,500 Thereafter 100,085 Total $ 310,562

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 4 - COMMITMENTS AND CONTINGENCIES In prior years, the Company entered into consulting agreements with one director, three executive officers, and one engineer of the Company, which include commitments to issue shares of the Company’s common stock from the Company’s Stock Incentive Plans. Two agreements have been terminated and shares have been issued in conjunction with the related separation agreements, but the vested shares related to the remaining consulting agreements with the two executive officers have not yet been issued in full, and therefore, remain a liability. According to the remaining three agreements, 1,319,000 2,400,000 2,400,000 1,200,000 In the event that the agreement is terminated by either party pursuant to the terms of the agreement, all unvested shares which have been earned shall vest on a pro-rata basis as of the effective date of the termination of the agreement and all unearned, unvested shares shall be terminated. The value of the shares was assigned at fair market value on the effective date of the agreement and the pro-rata number of shares earned was calculated and amortized at the end of each reporting period. The Company has accrued $ 361,800 730,836 On March 11, 2019, the Company’s Board of Directors approved the Consulting Agreement dated effective June 4, 2018 with its CEO. The term of the agreement is for three years beginning as of the effective date, unless terminated earlier pursuant to the agreement and is automatically renewable for one-year terms upon the consent of the parties. The services to be provided by the CEO pursuant to the agreement are those customary for the position in which the CEO is serving. As of the effective date, the Company shall issue to the CEO an aggregate of 3,060,000 1. 560,000 shares on the first-year anniversary of the effective date; 2. 1,000,000 shares on the second-year anniversary of the effective date; and 3. 1,500,000 shares on the third-year anniversary of the effective date. The shares are issued under the 2019 Stock Incentive Plan. Vesting of the shares is subject to acceleration of vesting upon the occurrence of certain events such as a Change of Control (as defined in the agreement) or the listing of the Company’s common stock on a senior exchange. As of September 30, 2021 and December 31, 2020, 3,060,000 1,560,000 On June 11, 2020, the Company entered into a Debt Forgiveness Agreement with the CEO, pursuant to which the CEO forgave $ 185,000 142,990 138,602 On March 11, 2019, the Company’s Board of Directors approved the Consulting Agreement dated effective October 1, 2018 with its COO. The term of the agreement is for three years beginning as of the effective date, unless terminated earlier pursuant to the agreement and is automatically renewable for one-year terms upon the consent of the parties. The services to be provided by the COO pursuant to the agreement are those customary for the position in which the COO is serving. As of the effective date, the Company shall issue to the COO an aggregate of 2,409,000 1. 409,000 shares on the first-year anniversary of the effective date; 2. 800,000 shares on the second-year anniversary of the effective date; and 3. 1,200,000 shares on the third-year anniversary of the effective date. The shares are issued under the 2017 Stock Incentive Plan. Vesting of the shares is subject to acceleration of vesting upon the occurrence of certain events such as a Change of Control (as defined in the agreement) or the listing of the Company’s common stock on a senior exchange. As of September 30, 2021 and December 31, 2020, 1,200,000 1,209,000 On June 11, 2020, the Company entered into a Debt Forgiveness Agreement with the COO, pursuant to which the COO forgave $ 103,250 127,864 139,078 On March 11, 2019, the Company’s Board of Directors approved the Amended and Restated Consulting Agreement dated effective April 1, 2018 with its CTO. The term of the agreement is for three years beginning as of the effective date, unless terminated earlier pursuant to the agreement and is automatically renewable for one-year terms upon the consent of the parties. The services to be provided by the CTO pursuant to the agreement are those customary for the position in which the CTO is serving. As of the effective date, the Company shall issue to the CTO an aggregate of 1,800,000 1. 300,000 shares on the first-year anniversary of the effective date; 2. 600,000 shares on the second-year anniversary of the effective date; and 3. 900,000 shares on the third-year anniversary of the effective date. On April 1, 2021, the Company and CTO mutually agreed to terminate the Amended and Restated Consulting Agreement. The Company and CTO agreed to settle for 843,288 270,493 843,288 0 900,000 On June 11, 2020, the Company entered into a Debt Forgiveness Agreement with the CTO pursuant to which the CTO forgave $ 82,475 Effective March 31, 2021, the Company entered into a Termination Agreement (the “ Termination Agreement 11,144 130,451 843,288 0 129,590

CONVERTIBLE NOTES PAYABLE

CONVERTIBLE NOTES PAYABLE	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
CONVERTIBLE NOTES PAYABLE	NOTE 5 - CONVERTIBLE NOTES PAYABLE The following table summarizes the outstanding balance of convertible notes payable, interest and conversion rates as of September 30, 2021 and December 31, 2020, respectively. Schedule of convertible notes payable September 30, 2021 December 31, 2020 A. Convertible note payable to an investor with interest at 12% per annum, convertible at any time into shares of common stock at $0.01 per share. Interest is payable quarterly with the balance of principal and interest due on maturity on March 1, 2022. The note is secured by substantially all the assets of the Company. $ 295,000 $ 600,000 B. Convertible note payable to an investor with interest at 5% per annum, convertible at any time into shares of common stock at $0.00084 per share. Interest is payable annually with the balance of principal and interest due on maturity on March 1, 2022. The note is secured by substantially all the assets of the Company. 55,000 55,000 C. Convertible note payable to an investor with interest at 12% per annum. On February 3, 2021, the investor settled the note and accrued interest, in exchange of common stock of the Company. – 50,000 D. Convertible note payable to an investor with interest at 12% per annum. $10,000 of the principal is currently convertible into shares of common stock at $0.01 per share, with remaining principal and interest convertible into shares of common stock at $0.01 per share. Interest is payable quarterly with the balance of principal and interest due on maturity on March 1, 2022. The note is secured by substantially all the assets of the Company. 50,000 60,000 E. Convertible notes payable to a related party with interest at 12% per annum, convertible at any time into shares of common stock at $0.00084 per share. Interest is payable quarterly with the balance of principal and interest due on maturity on August 2, 2022. The notes are secured by substantially all the assets of the Company. 125,000 125,000 F. Convertible note payable to an investor with interest at 10% per annum, convertible at any time into shares of common stock at $0.01 per share. Principal and interest due on maturity on April 29, 2022. 33,167 100,000 G. Convertible note payable to an investor with interest at 10% per annum, convertible at any time into shares of common stock at $0.0099 per share. Note was issued as payment for future fees to be incurred under the related Equity Financing Agreement. Principal and interest due on maturity on April 29, 2022. 75,000 75,000 633,167 1,065,000 Less unamortized discount (202,048 ) (111,781 ) Net balance 431,119 953,219 Less current portion (431,119 ) (953,219 ) $ – $ – A. January 18, 2018 Convertible Note and Warrants (“Note A”) On January 28, 2021, the noteholder of Note A agreed to extend the maturity date of the Senior Secured Convertible Promissory Note to March 1, 2022 0.01 100,000 300,000 500,000 On February 4, 2021, the noteholder A converted the principal balance of $ 50,000 5,000,000 75,000 7,500,000 80,000 8,000,000 The Company amortized the beneficial conversion feature discount to interest expense of $ 69,521 3,032 187,115 9,030 114,861 1,978 9,659 18,148 36,289 52,554 122,114 85,824 The principal balance payable on Note A amounted to $ 295,000 600,000 B. January 2019 Convertible Note and Warrants (“Note B”) The Company recorded interest expense of $ 693 693 2,057 2065 7,398 5,342 55,000 55,000 C. March 2019 Convertible Note and Warrants (Note C”) On January 28, 2021, the noteholder of Note C agreed to extend the maturity date of the Senior Secured Convertible Promissory Note to March 1, 2022 0.01 10,000 30,000 0 0 30,000 1,019 0 0 0 1,815 460 6,685 0 6,050 On January 28, 2021, the noteholder of Note C converted the principal balance of $ 40,000 6,510 4,650,978 0 50,000 D. March 2019 Convertible Note and Warrants (“Note D”) On January 28, 2021, the noteholder of Note D agreed to extend the maturity date of the Senior Secured Convertible Promissory Note to March 1, 2022 0.01 10,000 30,000 50,000 6,952 0 18,514 1,019 11,486 0 1,512 1,815 4,603 5,255 13,185 6,768 50,000 60,000 E. August 2019 Convertible Note and Warrants (“Note E”) On August 2, 2021, the noteholder of Note E agreed to extend the maturity date of the Senior Secured Convertible Promissory Note to August 2, 2022. All other terms and conditions of the Note E remain the same. The Company amortized the debt discount on Note E to interest expense of $ 5,855 13,207 34,104 39,335 0 34,104 3,781 3,781 11,219 11,260 29,909 18,690 125,000 125,000 August 2, 2022 F. July 2020 Equity Financing Arrangement (“Note F”) On February 1, 2021, the noteholder of Note F converted the principal balance of $ 66,833 5,177 7,200,000 836 1,726 3,067 1,726 876 2,986 33,167 100,000 October 29, 2021 G . July 2020 Equity Financing Arrangement (“Note G”) In connection with entering into the Equity Financing Agreement, on July 29, 2020, the Company issued to the investor a Convertible Promissory Note in the principal amount of $ 75,000 Note G The Company recorded interest expense of $ 1,890 1,295 5,610 1,295 7,849 5,240 75,000 October 29, 2021

EARNINGS (LOSS) PER SHARE

EARNINGS (LOSS) PER SHARE	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
EARNINGS (LOSS) PER SHARE	NOTE 6 - EARNINGS (LOSS) PER SHARE The following table sets forth the computation of basic and diluted net loss per share of common stock for the three months and nine months ended September 30, 2021 and 2020: Schedule of earnings per share Three Months ended 2021 2020 Net loss attributable to common stockholders (basic) $ (331,433 ) $ (329,866 ) Shares used to compute net loss per common share, basic and diluted 209,650,048 98,736,959 Net loss per share attributable to common stockholders, basic and diluted $ (0.00 ) $ (0.00 ) Nine Months ended 2021 2020 Net loss attributable to common stockholders (basic) $ (818,211 ) $ (1,504,004 ) Shares used to compute net loss per common share, basic and diluted 188,036,903 99,156,375 Net loss per share attributable to common stockholders, basic and diluted $ (0.00 ) $ (0.02 ) Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common shares and common share equivalents outstanding for the period. Common stock equivalents are only included when their effect is dilutive. The Company’s potentially dilutive securities which include stock options, convertible debt, convertible preferred stock and common stock warrants have been excluded from the computation of diluted net loss per share as they would be anti-dilutive. For all periods presented, there is no difference in the number of shares used to compute basic and diluted shares outstanding due to the Company’s net loss position. The following outstanding common stock equivalents have been excluded from diluted net loss per common share for the nine months ended September 30, 2021 and 2020, respectively, because their inclusion would be anti-dilutive: Schedule of anti-dilutive shares As of September 30, 2021 2020 Warrants to purchase common stock 2,868,397 2,868,397 Potentially issuable shares related to convertible notes payable 322,132,917 276,882,256 Potentially issuable vested shares to directors and officers – 2,869,000 Potentially issuable unvested shares to officers 1,200,000 4,400,000 Potentially issuable vested shares to a consultant 150,000 – Total anti-dilutive common stock equivalents 326,351,314 287,019,653

PAYCHECK PROTECTION PROGRAM LOA

PAYCHECK PROTECTION PROGRAM LOAN	9 Months Ended
	Sep. 30, 2021
Paycheck Protection Program Loan
PAYCHECK PROTECTION PROGRAM LOAN	NOTE 7 - PAYCHECK PROTECTION PROGRAM LOAN The Company applied for and received funding from the Payroll Protection Program (the “ PPP Loan 36,700 CARES Act April 23, 2022 1.0 36,700 Supplemental Target Advance On July 7, 2021 and July 8, 2021, a commercial bank granted to the Company two payments of $5,000 each, under the authority and regulations of the U. S. Small Business Administration Supplemental Target Advance of the Coronavirus Aid, Relief, and Economic Security Act (The “CARES Act”). Such advances amounted to $10,000 and does not need to be repaid. The Company recorded $ 10,000

RELATED PARTIES

RELATED PARTIES	9 Months Ended
	Sep. 30, 2021
Related Party Transactions [Abstract]
RELATED PARTIES	NOTE 8 - RELATED PARTIES At September 30, 2021 and December 31, 2020, respectively, the amount due to two stockholders was $ 1,000 The Company executed an operating lease to rent its current office facility from a stockholder on a month-to-month basis at a monthly rent of $250 starting January 1, 2020. The Company recorded rent expense of $ 750 750 2,250 2,250 750 18,000 The Company awarded shares payable to officers and a director valued at $ 60,060 183,219 349,657 545,673 361,800 730,836 702,986 2,343,288

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
STOCKHOLDERS' EQUITY	NOTE 9 - STOCKHOLDERS' EQUITY On January 4, 2021, pursuant to the authorization and approval previously provided by the stockholders, the Company filed a Certificate of Amendment to its Articles of Incorporation with the Secretary of State of Nevada to increase its authorized shares of common stock, $ 0.001 1,000,000,000 10,000,000 0.001 Common Stock Holders of shares of common stock are entitled to one vote for each share on all matters to be voted on by the stockholders. Holders of common stock do not have cumulative voting rights. Holders of common stock are entitled to share ratably in dividends, if any, as may be declared from time to time by the Board of Directors in its discretion from funds legally available, therefore. In the event of liquidation, dissolution, or winding up of the Company, the holders of common stock are entitled to share pro rata in all assets remaining after payment in full of all liabilities. All of the outstanding shares of common stock are fully paid and non-assessable. Holders of common stock have no preemptive rights to purchase the Company’s common stock. There are no conversion or redemption rights or sinking fund provisions with respect to the common stock. On January 28, 2021, the noteholder of Note C converted the principal balance of $ 40,000 6,510 4,650,978 On February 1, 2021, the noteholder of Note F converted the principal balance of $ 66,833 5,177 7,200,000 On February 4, 2021, the noteholder of Note A converted the principal balance of $ 50,000 5,000,000 On February 24, 2021, the Company entered into a Common Stock Purchase Agreement with an investor pursuant to which the investor agreed to purchase up to $ 5,000,000 0.015 8,000,000 8,400,000 8,900,000 10,200,000 120,000 126,000 133,500 153,000 On April 1, 2021, the Company’s Chief Technology Officer resigned from his employment with the Company. In settlement of the Company’s total obligations with the officer upon separation, the Company issued 843,288 252,986 On April 15, 2021, the noteholder of Note A converted the principal balance of $ 75,000 7,500,000 On May 20, 2021, the Company issued to a consultant for services rendered, pursuant to a consulting agreement, 500,000 7,800 On May 20, 2021, the Company issued to a consultant for services, pursuant to a consulting agreement, 50,000 900 On June 15, 2021, the Company issued 1,500,000 450,000 On July 28, 2021, the noteholder of Note A converted the principal balance of $ 80,000 8,000,000 As a result of all common stock issuances, the Company recorded 215,854,396 145,110,130 Stock Incentive Plans On December 14, 2017, the Board of Directors of the Company approved the 2017 Stock Incentive Plan (the “ 2017 Plan 4,500,000 On March 11, 2019, the Board of Directors of the Company approved the 2019 Stock Incentive Plan (the “ Plan 5,000,000 Shares earned and issued related to the consulting agreements are issued under the 2017 Stock Incentive Plan and the 2019 Stock Incentive Plan (Note 4). Vesting of the shares is subject to acceleration of vesting upon the occurrence of certain events such as a Change of Control (as defined in the agreement) or the listing of the Company’s common stock on a senior exchange. A summary of the status of the Company’s non-vested shares as of September 30, 2021 and 2020, and changes during the nine months period then ended, is presented below: Summary of non-vested shares Non-vested Shares of Common Stock Weighted Average Fair Value Balance at December 31, 2019 6,000,000 $ 0.30 Awarded – – Vested (1,600,000 ) $ 0.30 Forfeited – – Balance at September 30, 2020 4,400,000 $ 0.30 Balance at December 31, 2020 3,600,000 $ 0.30 Awarded – – Vested (3,600,000 ) $ 0.30 Forfeited – – Balance at September 30, 2021 – $ 0.30 Preferred Stock Series A Supervoting Convertible Preferred Stock On July 2, 2020, the Board of Directors of the Company authorized the issuance of 15,600 0.001 Dividends: Liquidation and Redemption Rights: Conversion: Rank: Voting Rights: A. If at least one share of Series A Super Voting Preferred Stock is issued and outstanding, then the total aggregate issued shares of Series A Super Voting Preferred Stock at any given time, regardless of their number, shall have voting rights equal to 20 times the sum of: i) the total number of shares of Common stock which are issued and outstanding at the time of voting, plus ii) the total number of shares of all Series of Preferred stocks which are issued and outstanding at the time of voting. B. Each individual share of Series A Super Voting Preferred Stock shall have the voting rights equal to: twenty times the sum of: {all shares of Common stock issued and outstanding at the time of voting + all shares of Series A and any newly designated Preferred stock issued and outstanding at the time of voting} Divided by: the number of shares of Series A Super Voting Preferred Stock issued and outstanding at the time of voting With respect to all matters upon which stockholders are entitled to vote or to which stockholders are entitled to give consent, the holders of the outstanding shares of Series A Super Voting Preferred Stock shall vote together with the holders of Common Stock without regard to class, except as to those matters on which separate class voting is required by applicable law or the Articles of Incorporation or Bylaws. The Company did not issue any Series A Supervoting Convertible Preferred Stock during the nine months ended September 30, 2021. The Company had 25,845 shares of Series A Supervoting Convertible Preferred Stock issued and outstanding at September 30, 2021 and December 31, 2020, respectively. Series B Convertible Preferred Stock Equity Financing On November 16, 2020, the Board of Directors of the Company authorized the issuance of up to 600 0.001 1,200 Dividends: Dividend End Date Voting Rights: Liquidation: Liquidation Conversion: Redemption: · 115% of the stated value if the redemption takes place within 90 days of issuance; · 120% of the stated value if the redemption takes place after 90 days and within 120 days of issuance · 125% of the stated value if the redemption takes place after 120 days and within 180 days of issuance; and · each share of Preferred Stock is redeemed one year from the day of issuance On November 19, 2020, pursuant to the terms of a Securities Purchase Agreement dated November 16, 2020 (the “ SPA GHS COD The Company’s ability to conduct additional closings under the SPA is subject to certain conditions, including the following: · The Company’s continued compliance with all covenants and agreements under the SPA and the COD, with no uncured defaults under the Company’s agreements with GHS; · The continued quotation of the Company’s common stock on the over-the-counter market or another trading market or exchange; · The average daily dollar trading volume for the Company’s common stock for the 30 trading days preceding each additional closing must be at least $10,000 per day; and · The closing market price for the Company’s common stock must be at least $0.01 for each of the 30 trading days preceding each additional closing. No additional closings may take place after the two-year anniversary of the SPA, or once the entire $600,000 amount has been funded. If the average daily dollar trading volume for the Company’s common stock for the 30 trading days preceding a particular additional closing is at least $50,000 per day, the Company may, at its option, increase the amount of that additional closing to 75 shares of Series B Convertible Preferred Stock ($75,000). The Series B Convertible Preferred Stock is classified as temporary equity, as it is convertible upon issuance at an amount equal to the lowest traded price for the Company’s common stock for the fifteen trading days immediately preceding the date of conversion. Based on the requirements of ASC 815, Derivatives and Hedging On November 19, 2020 (the date of receipt of cash proceeds of $45,000 issuance), the Company valued the conversion feature of the derivative and recorded an initial derivative liability of $ 103,267 58,267 39,000 84,000 7,755 79,211 2,541 7,539 On November 19, 2020, at December 31, 2020, March 31, 2021, June 30, 2021, and September 30, 2021, the Company valued the conversion feature using the Black-Scholes option pricing model with the following assumptions: conversion exercise prices ranging from $ 0.0051 0.0141 0.0083 0.0184 0 200.59 440.99 0.07 0.39 0.63 1.38 On December 16, 2020, pursuant to the terms of the SPA, GHS purchased an additional 85 shares of Series B Convertible Preferred Stock for gross proceeds of $ 85,000 On December 16, 2020 (the date of receipt of cash proceeds of $85,000 issuance), the Company valued the conversion feature of the derivative and recorded an initial derivative liability of $ 106,241 1,700 On December 16, 2020, December 31, 2020, March 31, 2021, June 30, 2021 and September 30, 2021, the Company valued the conversion feature using the Black-Scholes option pricing model with the following assumptions: conversion exercise prices ranging from $ 0.0060 0.0141 0.0063 0.0184 0 200.59 437.59 0.07 0.39 0.96 1.50 As a result of receipt of cash proceeds relating to Series B Convertible Preferred Stock, the Company recorded derivative liability of $ 143,224 315,782 18,357 1,653 Warrants A summary of the status of the Company’s warrants as of September 30, 2021 and December 31, 2020, and changes during the three months then ended, is presented below: Summary of warrant activity Shares Under Warrants Weighted Average Exercise Price Weighted Average Remaining Contractual Life Outstanding at December 31, 2019 1,627,532 $ 0.21 4.5 Issued 43,082,532 0.01 4.4 Exercised – – Expired/Forfeited (41,666,667 ) – Outstanding at September 30, 2020 3,043,397 $ 0.012292 4.0 Outstanding at December 31, 2020 – – Issued 2,868,397 $ 0.00084 3.4 Exercised – – Expired/Forfeited – – Outstanding at September 30, 2021 2,868,397 $ 0.00084 2.7

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2021
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 10 - SUBSEQUENT EVENTS Management has evaluated subsequent events through the date of this Report, the date the financial statements were available to be issued, noting the following items that would impact the accounting for events or transactions in the current period or require additional disclosure. On October 1, 2021, the Consulting Agreement, as amended, with the Company’s COO terminated by its terms (Note 4). On November 3, 2021, the Company received a notification from Small Business Administration forgiving the principal amount loan of $36,700 provided to the Company under the CARES Act on April 16, 2020. On November 4, 2021, the noteholder of Note F and Note G further agreed to extend the maturity date of the Note F and Note G from October 29, 2021 to April 29, 2022 in exchange of receiving 1,250,000 shares of common stock as commitment fee for extending the maturity dates of both Note F and Note G, respectively (Note 5).

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Interim Financial Statements	Interim Financial Statements The accompanying unaudited condensed interim financial statements and related notes have been prepared in accordance with GAAP for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission with respect to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited financial statements of the Company for the year ended December 31, 2020.
Principles of Consolidation	Principles of Consolidation The condensed consolidated financial statements for September 30, 2021 and 2020, respectively, include the accounts of Company, and its wholly-owned subsidiaries OXYS Corporation and HereLab, Inc. All significant intercompany balances and transactions have been eliminated.
Reclassifications	Reclassifications Certain amounts in the prior periods presented have been reclassified to conform to the current period financial statement presentation. These reclassifications have no effect on previously reported net income.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the valuation of accounts payable, accrued liabilities and payable to related party. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents. The Company reported a cash balance of $ 103,013 103,074
Accounts Receivable and Allowance for Doubtful Accounts	Accounts Receivable and Allowance for Doubtful Accounts Trade accounts receivable are carried at original invoice amount less an estimate made for doubtful accounts. The Company determines the allowance for doubtful accounts by identifying potential troubled accounts and by using historical experience and future expectations applied to an aging of accounts. Trade accounts receivable are written off when deemed uncollectible. Recoveries of trade accounts receivable previously written off are recorded as income when received. The Company recorded accounts receivable of $ 5,280 0 no
Long-Lived Assets	Long-Lived Assets The Company regularly reviews the carrying value and estimated lives of its long-lived assets to determine whether indicators of impairment may exist that warrant adjustments to the carrying value or estimated useful lives. The determinants used for this evaluation include management’s estimate of the asset’s ability to generate positive income from operations and positive cash flow in future periods as well as the strategic significance of the assets to the Company’s business objectives. Definite-lived intangible assets are amortized on a straight-line basis over the estimated periods benefited and are reviewed when appropriate for possible impairment.
Basic and Diluted Earnings (Loss) Per Common Share	Basic and Diluted Earnings (Loss) Per Common Share The Company computes earnings (loss) per share in accordance with Financial Accounting Standards Board Accounting Standards Codification (“ ASC Earnings per Share” EPS
Revenue Recognition	Revenue Recognition The Company’s revenue is derived primarily from providing services under contractual agreements. The Company recognizes revenue in accordance with ASC Topic No. 606, Revenue from Contracts with Customers According to ASC 606, the Company recognizes revenue based on the following criteria: · Identification of a contract or contracts, with a customer. · Identification of the performance obligations in the contract. · Determination of contract price. · Allocation of transaction price to the performance obligation. · Recognition of revenue when, or as, performance obligation is satisfied. The Company used a practical expedient available under ASC 606-10-65-1(f)4 that permits it to consider the aggregate effect of all contract modifications that occurred before the beginning of the earliest period presented when identifying satisfied and unsatisfied performance obligations, transaction price, and allocating the transaction price to the satisfied and unsatisfied performance obligations. The Company has elected to treat shipping and handling activities as cost of sales. Additionally, the Company has elected to record revenue net of sales and other similar taxes.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially expose the Company to concentrations of risk consist primarily of cash and cash equivalents which are generally not collateralized. The Company’s policy is to place its cash and cash equivalents with high quality financial institutions, in order to limit the amount of credit exposure. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“ FDIC 250,000 no
Fair Value of Financial Instruments and Fair Value Measurements	Fair Value of Financial Instruments and Fair Value Measurements ASC 820, “ Fair Value Measurements and Disclosures”, Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data. If the asset or liability has a specified (contractual) term, the Level 2 input must be observable for substantially the full term of the asset or liability. Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. The Company’s condensed consolidated financial instruments consist of cash and cash equivalents, prepaid expenses, accounts payable, accrued liabilities, notes payable and related parties payable. The Company believes that the recorded values of all the financial instruments approximate their current fair values because of their nature and respective maturity dates or durations.
Income Taxes	Income Taxes The Company accounts for income taxes using the asset and liability method in accordance with ASC 740, “ Income Taxes” The Company follows the provisions of ASC 740-10, “ Accounting for Uncertain Income Tax Positions
Convertible Debt and Convertible Preferred Stock	Convertible Debt and Convertible Preferred Stock When the Company issues convertible debt or convertible preferred stock, it first evaluates the balance sheet classification of the convertible instrument in its entirety to determine whether the instrument should be classified as a liability under ASC 480, Distinguishing Liabilities from Equity Derivatives and Hedging If a conversion feature does not meet the conditions to be separated and accounted for as an embedded derivative liability, the Company then determines whether the conversion feature is “beneficial”. A conversion feature would be considered beneficial if the conversion feature is “in the money” when the host instrument is issued or, under certain circumstances, later. If convertible debt contains a beneficial conversion feature (“ BCF When a convertible preferred stock contains a BCF, after allocating the proceeds to the BCF, the resulting discount is either amortized over the period beginning when the convertible preferred stock is issued up to the earliest date the conversion feature may be exercised, or if the convertible preferred stock is immediately exercisable, the discount is fully amortized at the date of issuance. The amortization is recorded similar to a dividend. Convertible debt is accounted for under the ASC 470-20, Debt – Debt with Conversion and Other Options.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In December 2019, the Financial Accounting Standards Board issued Accounting Standards Update (“ ASU Income Taxes (Topic 740) In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU also removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and simplifies the diluted earnings per share calculation in certain areas. The amendments in this ASU are effective for annual and interim periods beginning after December 15, 2023, although early adoption is permitted. The Company is in the process of evaluating the impact of this new guidance on its financial statements. Other accounting standards that have been issued or proposed by FASB and do not require adoption until a future date are not expected to have a material impact on the consolidated financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.

INTANGIBLE ASSETS (Tables)

INTANGIBLE ASSETS (Tables)	9 Months Ended
	Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets Net of Amortization	Intangible Assets Net of Amortization September 30, 2021 December 31, 2020 Intangible Assets $ 495,000 $ 495,000 Accumulated amortization (184,438 ) (147,144 ) Intangible Assets, net $ 310,562 $ 347,856
Schedule of future amortization	Schedule of future amortization Amortization expense 2021 $ 12,477 2022 49,500 2023 49,500 2024 49,500 2025 49,500 Thereafter 100,085 Total $ 310,562

CONVERTIBLE NOTES PAYABLE (Tabl

CONVERTIBLE NOTES PAYABLE (Tables)	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Schedule of convertible notes payable	Schedule of convertible notes payable September 30, 2021 December 31, 2020 A. Convertible note payable to an investor with interest at 12% per annum, convertible at any time into shares of common stock at $0.01 per share. Interest is payable quarterly with the balance of principal and interest due on maturity on March 1, 2022. The note is secured by substantially all the assets of the Company. $ 295,000 $ 600,000 B. Convertible note payable to an investor with interest at 5% per annum, convertible at any time into shares of common stock at $0.00084 per share. Interest is payable annually with the balance of principal and interest due on maturity on March 1, 2022. The note is secured by substantially all the assets of the Company. 55,000 55,000 C. Convertible note payable to an investor with interest at 12% per annum. On February 3, 2021, the investor settled the note and accrued interest, in exchange of common stock of the Company. – 50,000 D. Convertible note payable to an investor with interest at 12% per annum. $10,000 of the principal is currently convertible into shares of common stock at $0.01 per share, with remaining principal and interest convertible into shares of common stock at $0.01 per share. Interest is payable quarterly with the balance of principal and interest due on maturity on March 1, 2022. The note is secured by substantially all the assets of the Company. 50,000 60,000 E. Convertible notes payable to a related party with interest at 12% per annum, convertible at any time into shares of common stock at $0.00084 per share. Interest is payable quarterly with the balance of principal and interest due on maturity on August 2, 2022. The notes are secured by substantially all the assets of the Company. 125,000 125,000 F. Convertible note payable to an investor with interest at 10% per annum, convertible at any time into shares of common stock at $0.01 per share. Principal and interest due on maturity on April 29, 2022. 33,167 100,000 G. Convertible note payable to an investor with interest at 10% per annum, convertible at any time into shares of common stock at $0.0099 per share. Note was issued as payment for future fees to be incurred under the related Equity Financing Agreement. Principal and interest due on maturity on April 29, 2022. 75,000 75,000 633,167 1,065,000 Less unamortized discount (202,048 ) (111,781 ) Net balance 431,119 953,219 Less current portion (431,119 ) (953,219 ) $ – $ –

EARNINGS (LOSS) PER SHARE (Tabl

EARNINGS (LOSS) PER SHARE (Tables)	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Schedule of earnings per share	Schedule of earnings per share Three Months ended 2021 2020 Net loss attributable to common stockholders (basic) $ (331,433 ) $ (329,866 ) Shares used to compute net loss per common share, basic and diluted 209,650,048 98,736,959 Net loss per share attributable to common stockholders, basic and diluted $ (0.00 ) $ (0.00 ) Nine Months ended 2021 2020 Net loss attributable to common stockholders (basic) $ (818,211 ) $ (1,504,004 ) Shares used to compute net loss per common share, basic and diluted 188,036,903 99,156,375 Net loss per share attributable to common stockholders, basic and diluted $ (0.00 ) $ (0.02 )
Schedule of anti-dilutive shares	Schedule of anti-dilutive shares As of September 30, 2021 2020 Warrants to purchase common stock 2,868,397 2,868,397 Potentially issuable shares related to convertible notes payable 322,132,917 276,882,256 Potentially issuable vested shares to directors and officers – 2,869,000 Potentially issuable unvested shares to officers 1,200,000 4,400,000 Potentially issuable vested shares to a consultant 150,000 – Total anti-dilutive common stock equivalents 326,351,314 287,019,653

STOCKHOLDERS' EQUITY (Tables)

STOCKHOLDERS' EQUITY (Tables)	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Summary of non-vested shares	Summary of non-vested shares Non-vested Shares of Common Stock Weighted Average Fair Value Balance at December 31, 2019 6,000,000 $ 0.30 Awarded – – Vested (1,600,000 ) $ 0.30 Forfeited – – Balance at September 30, 2020 4,400,000 $ 0.30 Balance at December 31, 2020 3,600,000 $ 0.30 Awarded – – Vested (3,600,000 ) $ 0.30 Forfeited – – Balance at September 30, 2021 – $ 0.30
Summary of warrant activity	Summary of warrant activity Shares Under Warrants Weighted Average Exercise Price Weighted Average Remaining Contractual Life Outstanding at December 31, 2019 1,627,532 $ 0.21 4.5 Issued 43,082,532 0.01 4.4 Exercised – – Expired/Forfeited (41,666,667 ) – Outstanding at September 30, 2020 3,043,397 $ 0.012292 4.0 Outstanding at December 31, 2020 – – Issued 2,868,397 $ 0.00084 3.4 Exercised – – Expired/Forfeited – – Outstanding at September 30, 2021 2,868,397 $ 0.00084 2.7

NATURE OF OPERATIONS, BASIS O_2

NATURE OF OPERATIONS, BASIS OF PRESENTATION AND GOING CONCERN (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Accounting Policies [Abstract]
Net Cash Used by Operating Activities	$ 521,911	$ 41,717
Accumulated deficit	$ 8,298,889		$ 7,480,678

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	Sep. 30, 2021	Dec. 31, 2020	Sep. 30, 2020	Dec. 31, 2019
Accounting Policies [Abstract]
Cash and Cash Equivalents	$ 103,013	$ 103,074	$ 48,495	$ 24,212
Accounts receivable	5,280	0
Allowance for doubtful accounts	0	0
FDIC insured amount	250,000
Cash in excess of FDIC insurance	$ 0	$ 0

INTANGIBLE ASSETS (Details - In

INTANGIBLE ASSETS (Details - Intangible assets) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	$ 495,000	$ 495,000
Accumulated amortization	(184,438)	(147,144)
Intangible Assets, net	$ 310,562	$ 347,856

INTANGIBLE ASSETS (Details - Es

INTANGIBLE ASSETS (Details - Estimated future amortization expense)	Sep. 30, 2021USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2021	$ 12,477
2022	49,500
2023	49,500
2024	49,500
2025	49,500
Thereafter	100,085
Total	$ 310,562

INTANGIBLE ASSETS (Details Narr

INTANGIBLE ASSETS (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Finite-Lived Intangible Assets, Net	$ 310,562		$ 310,562		$ 347,856
Impairment of intangibe assets			$ 0	$ 0
Estimated useful life of intangibles			10 years
Amortization expense	$ 12,477	$ 12,477	$ 37,295	$ 37,159

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)	Apr. 12, 2021	Jun. 11, 2020	Apr. 02, 2021	Mar. 11, 2019	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019	Mar. 31, 2021
Other Commitments [Line Items]
Shares payable, value					$ 361,800		$ 730,836
Shares granted					0	43,082,532
Accrued expenses					$ 211,860		147,490
Consulting Agreement [Member]
Other Commitments [Line Items]
Common stock issued for past services			843,288
Common stock Fair value for fast service			$ 270,493
Number of shares issued	843,288
Termination Agreement [Member]
Other Commitments [Line Items]
Number of shares issued	843,288
Chief Executive Officer [Member]
Other Commitments [Line Items]
Debt Forgiveness		$ 185,000
Salaries payable					142,990		138,602
Chief Operating Officer [Member]
Other Commitments [Line Items]
Debt Forgiveness		103,250
Salaries payable					127,864		139,078
Chief Technology Officer [Member]
Other Commitments [Line Items]
Debt Forgiveness		$ 82,475
Salaries payable					$ 0		$ 129,590
Chief Technology Officer [Member] | Termination Agreement [Member]
Other Commitments [Line Items]
Reimbursable expenses									$ 11,144
Accrued expenses									$ 130,451
Plan 2019 [Member] | Chief Executive Officer [Member]
Other Commitments [Line Items]
Common stock shares vested					3,060,000		1,560,000
Shares granted				3,060,000
Plan 2019 [Member] | Chief Technology Officer [Member]
Other Commitments [Line Items]
Common stock shares vested					0		900,000
Shares granted				1,800,000
Plan 2017 [Member] | Chief Operating Officer [Member]
Other Commitments [Line Items]
Common stock shares vested					1,200,000		1,209,000
Shares granted				2,409,000
Convertible Promissory Note [Member]
Other Commitments [Line Items]
Shares payable, value					$ 361,800		$ 730,836
Convertible Promissory Note [Member] | Fye 2019 [Member]
Other Commitments [Line Items]
Common stock shares vested								1,319,000
Convertible Promissory Note [Member] | Fye 2020 [Member]
Other Commitments [Line Items]
Common stock shares vested							2,400,000
Convertible Promissory Note [Member] | Fye 2021 [Member]
Other Commitments [Line Items]
Common stock shares vested					2,400,000
Common stock shares nonvested					1,200,000

CONVERTIBLE NOTES PAYABLE (Deta

CONVERTIBLE NOTES PAYABLE (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Convertible note payable, gross	$ 633,167	$ 1,065,000
Less unamortized discount	(202,048)	(111,781)
Net balance	431,119	953,219
Less current portion	(431,119)	(953,219)
Convertible note payable, net	0	0
Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Convertible note payable, gross	295,000	600,000
Convertible Notes Payable One [Member]
Debt Instrument [Line Items]
Convertible note payable, gross	55,000	55,000
Convertible Notes Payable Two [Member]
Debt Instrument [Line Items]
Convertible note payable, gross	0	50,000
Convertible Notes Payable Three [Member]
Debt Instrument [Line Items]
Convertible note payable, gross	50,000	60,000
Convertible Notes Payable Four [Member]
Debt Instrument [Line Items]
Convertible note payable, gross	125,000	125,000
Convertible Notes Payable Five [Member]
Debt Instrument [Line Items]
Convertible note payable, gross	33,167	100,000
Convertible Notes Payable Six [Member]
Debt Instrument [Line Items]
Convertible note payable, gross	$ 75,000	$ 75,000

CONVERTIBLE NOTES PAYABLE (De_2

CONVERTIBLE NOTES PAYABLE (Details Narrative) - USD ($)	1 Months Ended						3 Months Ended		7 Months Ended	9 Months Ended
	Aug. 02, 2021	Jul. 28, 2021	Apr. 15, 2021	Feb. 04, 2021	Feb. 01, 2021	Jan. 28, 2021	Sep. 30, 2021	Sep. 30, 2020	Jul. 29, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Debt Instrument [Line Items]
Loss on extinguishment of debt							$ 0	$ (16,205)		$ 120,000	$ (16,205)
Amortization of discount										269,734	90,149
Convertible notes payble outstanding							431,119			431,119		$ 953,219
Note A [Member]
Debt Instrument [Line Items]
Debt maturity date						Mar. 1, 2022
Conversion price per share						$ 0.01
Loss on extinguishment of debt										100,000
Beneficial conversion feature						$ 300,000
Unamortized discount						$ 500,000	114,861			114,861		1,978
Number of shares converted, Principal value		$ 80,000	$ 75,000	$ 50,000
Number of shares converted		8,000,000	7,500,000	5,000,000
Amortization of discount							69,521	3,032		187,115	9,030
Interest Expense							9,659	18,148		36,289	52,554
Accrued interest							122,114			122,114		85,824
Convertible notes payble outstanding							295,000			295,000		600,000
Note B [Member]
Debt Instrument [Line Items]
Interest Expense							693	693		2,057	2,065
Accrued interest							7,398			7,398		5,342
Convertible notes payble outstanding							55,000			55,000		55,000
Note C [Member]
Debt Instrument [Line Items]
Debt maturity date						Mar. 1, 2022
Conversion price per share						$ 0.01
Loss on extinguishment of debt										10,000
Unamortized discount						$ 30,000	0			0		0
Number of shares converted, Principal value						$ 40,000
Number of shares converted						4,650,978
Amortization of discount							0	0		30,000	1,019
Interest Expense							0	1,815		460	6,685
Accrued interest							0			0		6,050
Convertible notes payble outstanding							0			0		50,000
Number of shares converted, Accued Interest						$ 6,510
Note D [Member]
Debt Instrument [Line Items]
Debt maturity date						Mar. 1, 2022
Conversion price per share						$ 0.01
Loss on extinguishment of debt										10,000
Beneficial conversion feature										30,000
Unamortized discount						$ 50,000	11,486			11,486		0
Amortization of discount							6,952	0		18,514	1,019
Interest Expense							1,512	1,815		4,603	5,255
Accrued interest							13,185			13,185		6,768
Convertible notes payble outstanding							50,000			50,000		60,000
Note E [Member]
Debt Instrument [Line Items]
Debt maturity date	Aug. 2, 2022
Unamortized discount							0			0		34,104
Amortization of discount							5,855	13,207		34,104	39,335
Interest Expense							3,781	3,781		11,219	11,260
Accrued interest							29,909			29,909		18,690
Convertible notes payble outstanding							125,000			125,000		125,000
Note F [Member]
Debt Instrument [Line Items]
Debt maturity date					Oct. 29, 2021
Number of shares converted, Principal value					$ 66,833
Number of shares converted					7,200,000
Interest Expense							836	1,726		3,067	1,726
Accrued interest							876			876		2,986
Convertible notes payble outstanding							33,167			33,167		100,000
Number of shares converted, Accued Interest					$ 5,177
Note G [Member]
Debt Instrument [Line Items]
Debt maturity date									Oct. 29, 2021
Interest Expense							1,890	$ 1,295		5,610	$ 1,295
Accrued interest							$ 7,849			$ 7,849		5,240
Convertible notes payble outstanding									$ 75,000			$ 75,000

EARNINGS (LOSS) PER SHARE (Deta

EARNINGS (LOSS) PER SHARE (Details - Per share info) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Earnings Per Share [Abstract]
Net loss attributable to common stockholders (basic)	$ (331,433)	$ (329,866)	$ (818,211)	$ (1,504,004)
Shares used to compute net loss per common share, basic and diluted	209,650,048	98,736,959	188,036,903	99,156,375
Net loss per share attributable to common stockholders, basic and diluted	$ 0	$ 0	$ 0	$ (0.02)

EARNINGS (LOSS) PER SHARE (De_2

EARNINGS (LOSS) PER SHARE (Details - Antidilutive Shares) - shares	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common stock equivalents	326,351,314	287,019,653
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common stock equivalents	2,868,397	2,868,397
Convertible Notes Payable [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common stock equivalents	322,132,917	276,882,256
Vested Shares [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common stock equivalents	0	2,869,000
Unvested Shares [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common stock equivalents	1,200,000	4,400,000
Vested Shares Consultant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common stock equivalents	150,000	0

PAYCHECK PROTECTION PROGRAM L_2

PAYCHECK PROTECTION PROGRAM LOAN (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Debt Instrument [Line Items]
Ppp Loan Current	$ 36,700		$ 36,700
Other income	$ 10,000	$ 0	10,000	$ 409
PPP Loan [Member]
Debt Instrument [Line Items]
Proceeds from loan			$ 36,700
Debt instrument, maturity date			Apr. 23, 2022
Debt instrument, interest rate			1.00%

RELATED PARTIES (Details Narrat

RELATED PARTIES (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Related Party Transaction [Line Items]
Shares issued, value	$ 153,000		$ 532,500
Professional expense paid	88,421	$ 240,919	464,917	$ 672,256
Directors And Officers [Member]
Related Party Transaction [Line Items]
Shares issued, value	60,060	183,219	349,657	545,673
Professional expense paid			361,800	730,836
Conversion of stock, amount issued			$ 702,986
Conversion of stock, shares issued			2,343,288
Stockholder [Member]
Related Party Transaction [Line Items]
Amount due to stockholders	1,000		$ 1,000		$ 1,000
Rent expense paid to stockholder	750	$ 750	2,250	$ 2,250
Account payable - related parties	$ 750		$ 750		$ 18,000

STOCKHOLDERS' EQUITY (Details -

STOCKHOLDERS' EQUITY (Details - non-vested shares) - $ / shares	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Equity [Abstract]
Options non-vested outstanding, beginning balance	3,600,000	6,000,000
Weighted Average Exercise Price, Options non-vested outstanding, beginning balance	$ 0.30	$ 0.30
Options awarded	0	0
Weighted Average Exercise Price, awarded	$ 0	$ 0
Options vested	(3,600,000)	(1,600,000)
Weighted Average Exercise Price, vested	$ 0.30	$ 0.30
Options forfeited	0	0
Weighted average exercise price, forfeited	$ 0	$ 0
Options non-vested outstanding, ending balance	0	4,400,000
Weighted Average Exercise Price, Options non-vested outstanding, ending balance	$ 0.30	$ 0.30

STOCKHOLDERS' EQUITY (Details_2

STOCKHOLDERS' EQUITY (Details - Warrants) - $ / shares	9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Equity [Abstract]
Warrants outstanding, beginning balance	2,868,397	1,627,532	1,627,532
Outstanding Weighted Average Exercise Price	$ 0.00084	$ 0.012292	$ 0.00084	$ 0.21
Weighted Average Remaining Contractual Life	2 years 8 months 12 days	4 years	3 years 4 months 24 days	4 years 6 months
Warrants issued	0	43,082,532
Issued, Weighted Average Exercise Price	$ 0	$ 0.01
Weighted Average Remaining Contractual Life, Issued		4 years 4 months 24 days
Warrants exercised		0
Exercised, Weighted Average Exercise Price		$ 0
Warrants expired/forfeited	0	(41,666,667)
Expired/Forfeited, Weighted Average Exercise Price	$ 0	$ 0
Warrants outstanding, ending balance	2,868,397	3,043,397	2,868,397	1,627,532
Outstanding, Weighted Average Exercise Price	$ 0.00084	$ 0.21	$ 0.21
Warrants expired/forfeited	0	41,666,667
Warrants outstanding, ending balance	2,868,397	3,043,397	2,868,397	1,627,532
Outstanding Weighted Average Exercise Price	$ 0.00084	$ 0.012292	$ 0.00084	$ 0.21

STOCKHOLDERS' EQUITY (Details N

STOCKHOLDERS' EQUITY (Details Narrative) - USD ($)	Aug. 03, 2021	Jun. 15, 2021	Apr. 14, 2021	Jul. 28, 2021	May 20, 2021	Apr. 15, 2021	Apr. 02, 2021	Mar. 16, 2021	Feb. 04, 2021	Feb. 02, 2021	Feb. 01, 2021	Jan. 28, 2021	Dec. 16, 2020	Nov. 19, 2020	Feb. 26, 2021	Feb. 24, 2021	Sep. 30, 2021	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2021	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Nov. 16, 2020	Jul. 02, 2020
Class of Stock [Line Items]
Common stock, par value																	$ 0.001	$ 0.001		$ 0.001	$ 0.001	$ 0.001		$ 0.001
Common stock, shares authorized																	1,000,000,000	1,000,000,000		1,000,000,000	1,000,000,000	1,000,000,000		1,000,000,000
Preferred stock, shares authorized																	10,000,000	10,000,000		10,000,000	10,000,000	10,000,000		10,000,000
Preferred stock, par value																	$ 0.001	$ 0.001		$ 0.001	$ 0.001	$ 0.001		$ 0.001
Stock issued duriing period, value																		$ 153,000				$ 532,500
Common stock, shares issued																	215,854,396	215,854,396		215,854,396	215,854,396	215,854,396		145,110,130
Common stock, shares outstanding																	215,854,396	215,854,396		215,854,396	215,854,396	215,854,396		145,110,130
Interest expense																		$ 100,701	$ 72,681			$ 333,039	$ 640,404
Proceeds from stock																						$ 521,850	$ 0
Series A Supervoting [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized																										15,600
Preferred stock, par value																										$ 0.001
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized																	600	600		600	600	600		600	600
Preferred stock, par value																	$ 1,200	$ 1,200		$ 1,200	$ 1,200	$ 1,200		$ 1,200	$ 0.001
Derivative liability													$ 106,241	$ 103,267			$ 143,224	$ 143,224		$ 143,224	$ 143,224	$ 143,224		$ 315,782
Loss on the derivative														58,267
Interest expense														39,000							1,700
Mezzanine liability														$ 84,000
Loss on change in fair market value of derivative liability																		7,755				79,211
Sales commission																		2,541				7,539
Dividend payable																	$ 18,357	$ 18,357		$ 18,357	$ 18,357	$ 18,357		1,653
Series B Convertible Preferred Stock [Member] | Minimum [Member]
Class of Stock [Line Items]
Exercise prices																	$ 0.0051	$ 0.0051		$ 0.0051	$ 0.0051	$ 0.0051
Valuation ranging																	$ 0.0063			$ 0.0083
Expected dividend yield																	0.00%			0.00%
Expected volatility																	200.59%			200.59%
Risk-free interest rates																	7.00%			7.00%
Expected term																	11 months 15 days			7 months 17 days
Series B Convertible Preferred Stock [Member] | Maximum [Member]
Class of Stock [Line Items]
Exercise prices																	$ 0.0141	0.0141		$ 0.0141	0.0141	0.0141
Valuation ranging																	$ 0.0184			$ 0.0184
Expected volatility																	437.59%			440.99%
Risk-free interest rates																	0.39%			0.39%
Expected term																	1 year 6 months			1 year 4 months 17 days
Series B Convertible Preferred Stock 1 [Member] | Minimum [Member]
Class of Stock [Line Items]
Exercise prices																	$ 0.0060	0.0060		$ 0.0060	0.0060	0.0060
Series B Convertible Preferred Stock 1 [Member] | Maximum [Member]
Class of Stock [Line Items]
Exercise prices																	$ 0.0141	$ 0.0141		$ 0.0141	$ 0.0141	$ 0.0141
Plan 2017 [Member]
Class of Stock [Line Items]
Shares authorized under the plan																	4,500,000	4,500,000		4,500,000	4,500,000	4,500,000
Plan 2019 [Member]
Class of Stock [Line Items]
Shares authorized under the plan																	5,000,000	5,000,000		5,000,000	5,000,000	5,000,000
Officer [Member]
Class of Stock [Line Items]
StockIssuedDuringPeriodSharesIssuedForServices							843,288
StockIssuedDuringPeriodValueIssuedForServices							$ 252,986
Securities Purchase Agr [Member]
Class of Stock [Line Items]
Proceeds from stock													$ 85,000
Note C [Member]
Class of Stock [Line Items]
Accrued interest																	$ 0	$ 0		$ 0	$ 0	$ 0		6,050
Number of shares converted												4,650,978
Number of shares converted, Principal value												$ 40,000
Note F [Member]
Class of Stock [Line Items]
Accrued interest																	876	876		876	876	876		2,986
Number of shares converted											7,200,000
Number of shares converted, Principal value											$ 66,833
Note A [Member]
Class of Stock [Line Items]
Accrued interest																	$ 122,114	$ 122,114		$ 122,114	$ 122,114	$ 122,114		$ 85,824
Number of shares converted				8,000,000		7,500,000			5,000,000
Number of shares converted, Principal value				$ 80,000		$ 75,000			$ 50,000
Noteholder [Member] | Note C [Member]
Class of Stock [Line Items]
Convertible notes payable, face amount												40,000
Accrued interest												$ 6,510
Number of shares converted												4,650,978
Noteholder [Member] | Note F [Member]
Class of Stock [Line Items]
Convertible notes payable, face amount									$ 50,000	$ 66,833
Accrued interest										$ 5,177
Number of shares converted									5,000,000	7,200,000
Investor [Member] | Stock Purchase Agreement [Member]
Class of Stock [Line Items]
Proceeds from convertible debt																$ 5,000,000
Share price																$ 0.015
Stock issued duriing period, shares	10,200,000		8,900,000					8,400,000							8,000,000
Stock issued duriing period, value	$ 153,000		$ 133,500					$ 126,000							$ 120,000
Consultant [Member]
Class of Stock [Line Items]
StockIssuedDuringPeriodSharesIssuedForServices					500,000
StockIssuedDuringPeriodValueIssuedForServices					$ 7,800
Consultant 1 [Member]
Class of Stock [Line Items]
StockIssuedDuringPeriodSharesIssuedForServices					50,000
StockIssuedDuringPeriodValueIssuedForServices					$ 900
Chief Executive [Member]
Class of Stock [Line Items]
Stock Issued During Period Shares Share Based Compensation		1,500,000
Shares Issued, Value Share Based Compensation		$ 450,000